Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beLP3 + EF-2001
- Development stage
- Preclinical
- Lead developer
- Bereum
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
beLP3 + EF-2001 is a parabiotic combination developed by the Korean company Bereum. It is composed of four heat-inactivated bacterial strains: *Lactobacillus plantarum*, *Lactobacillus casei*, and *Lactobacillus acidophilus* (collectively known as beLP3), along with *Enterococcus faecalis* (strain EF-2001). Unlike traditional probiotics, parabiotics (also known as postbiotics or heat-killed probiotics) consist of non-viable microbial cells or cell fragments that retain biological activity and provide health benefits, primarily through immunomodulation and interaction with the gut microbiota. This specific 4-strain mixture is marketed as a B2B ingredient for use in pharmaceuticals, functional foods, cosmetics, and animal feed. It is currently undergoing human clinical trials to evaluate its efficacy and safety in various health applications.
- Brand names
- 베름 4종 파라바이오틱스
- Other names
- parabiotics4-strain parabioticsBereum 4-strain parabioticsBereum4-strain parabioticsBereum-4-strain parabiotics
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on beLP3 + EF-2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beLP3 + EF-2001.